News - TOSP

Find Out The Latest

Welcome to the latest news from The Oxford Science Park, where you can keep up to date with developments across our community. From company milestones and scientific breakthroughs to investment news, partnerships, events and Park announcements, discover how our occupiers are advancing innovation and shaping the future.

Media enquiries: comms@oxfordsp.com

Welcoming UK Agri-Tech Centre to The Oxford Science Park

01 Sep 2026

The Oxford Science Park is pleased to welcome the UK Agri-Tech Centre, which joined the Park earlier this year. The UK Agri-Tech Centre supports agri-tech companies to prove, build and scale technologies that address the challenges facing agriculture, horticulture and aquaculture. By connecting businesses with farmers, growers, researchers, investors and industry partners, it helps promising technologies move from development and testing... Read more

Scancell receives UK approval to begin Phase 3 melanoma trial

25 Aug 2026

Scancell, a clinical-stage immuno-oncology company based at The Oxford Science Park, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase 3 clinical trial of its lead cancer treatment, iSCIB1+, in patients with advanced melanoma. The trial is an important step towards potentially bringing iSCIB1+ to patients. It is expected to involve 550 people with advanced melanoma across around 90... Read more

The Oxford Science Park welcomes new Managing Director

24 Aug 2026

The Oxford Science Park is pleased to welcome James Evans as its new Managing Director. James joins from Longfellow Real Estate Partners, where he was a Senior Director leading the company's operational activities in the UK, overseeing portfolio management, asset management, leasing and property management. As part of this, he managed CamLIFE, a 42-acre, 250,000 sq ft innovation campus on the outskirts of Cambridge. As Managing Director,... Read more

Vivid Dx secures $15 million investment and appoints new CEO

29 Jul 2026

Vivid Dx, based at The Oxford Science Park, has secured $15 million in seed funding to accelerate the development of its rapid diagnostic technology for life-threatening infections, and has appointed Keith O'Neill as its new Chief Executive Officer. The company is developing a platform that uses artificial intelligence (AI) and Raman spectroscopy to identify infection-causing pathogens directly from blood samples and determine which... Read more

Scancell and Neuphoria Therapeutics announce merger agreement and financing

23 Jul 2026

Scancell has announced a merger with US-based Neuphoria Therapeutics and plans to secure up to $89 million in financing to support the next stage of its lead cancer treatment programme. The all-share merger will see Scancell acquire Neuphoria Therapeutics, creating a combined company that will continue to operate as Scancell. Subject to shareholder approval, the combined business will be listed on the Nasdaq stock exchange in the United... Read more